The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma
Open accessAbstract
BACKGROUND: Hepatocellular carcinoma (HCC) results in more than 600,000 deaths per year. Transarterial embolisation (TAE) and transarterial chemoembolisation (TACE) have become standard loco-regional treatments for unresectable HCC. OBJECTIVES: To assess the beneficial and harmful effects of TACE or TAE. SEARCH STRATEGY: We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Cancer Network register, The Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, Science Citation Index Expanded, and The Latin American Caribbean Health Sciences Literature (LILACS) from dates of inceptions up to September 2010. SELECTION CRITERIA: We considered for inclusion all randomised trials that compared TACE or TAE versus placebo, sham, or no intervention. Co-interventions were allowed if comparable between intervention groups. Trials with inadequate randomisation were excluded. DATA COLLECTION AND ANALYSIS: For all-cause mortality, we calculated the log hazard ratio (HR) with standard error as point estimate and pooled them for meta-analysis using the inverse variance method. Sub-group analyses were performed regarding intervention regimen, trial truncation, or co-interventions. We validated the results with trial sequential analyses. We used random-effects model in all meta-analyses in anticipation of statistical heterogeneity among the trials. MAIN RESULTS: We included nine trials with 645 participants. Six trials assessed TACE versus control and three trials assessed TAE versus control. Seven trials had low risk of selection bias based on adequate generation of allocation sequence and concealment - but all these trials had other risks of bias. Three trials were stopped early due to interim inspections and one due to slow accrual. For all-cause mortality, statistical heterogeneity between trials was low to moderate (I(2)= 30%). Meta-analysis of trials with low risk of selection bias showed that TACE or TAE versus control does not significantly increase survival (HR 0.88; 95% CI 0.71 to 1.10). Two trials with low risk of selection bias, no early stopping, and no co-intervention did not establish any significant effect of TACE or TAE on overall survival (hazard ratio 1.22, 95% confidence interval 0.82 to 1.83; P = 0.33). Trial sequential analysis confirmed the absence of evidence for a beneficial effect of TACE or TAE on survival indicating the need for future randomisation of up to 383 additional participants. Substantial differences in criteria for assessing tumour response did not allow quantitative analyses. One trial investigated quality of life but did not detect any significant differences between the intervention groups. A range of adverse events including post-embolisation syndrome and serious complications were reported. AUTHORS' CONCLUSIONS: There is no firm evidence to support or refute TACE or TAE for patients with unresectable HCC. More adequately powered and bias-protected trials are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Cheng, B.-Q., Jia, C.-Q., Liu, C.-T., Fan, W., Wang, Q.-L., Zhang, Z.-L., & Yi, C.-H. (2008) · JAMA · doi:10.1001/jama.299.14.1669 · Cited by 190
RetractedBias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Practical methods for incorporating summary time-to-event data into meta-analysis.
Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S., & Sydes, M. R. (2007) · Trials · doi:10.1186/1745-6215-8-16 · Cited by 6,208
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089
(2008) · Cited by 3,790
Llovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560
Llovet, J. M., Real, M. I., Montaña, X., Planas, R., Coll, S., Aponte, J., Ayuso, C., Sala, M., Muchart, J., Solà, R., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08649-x · Cited by 3,494
Interaction revisited: the difference between two estimates.
Altman, D. G., & Bland, J. M. (2003) · BMJ · doi:10.1136/bmj.326.7382.219 · Cited by 3,203
Llovet, J. M., & Bruix, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50047 · Cited by 3,029
Evaluating non-randomised intervention studies
Deeks, J., Dinnes, J., D'Amico, R., Sowden, A., Sakarovitch, C., Song, F., Petticrew, M., & Altman, D. (2003) · Health Technology Assessment · doi:10.3310/hta7270 · Cited by 2,907
Rising Incidence of Hepatocellular Carcinoma in the United States
El-Serag, H. B., & Mason, A. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401001 · Cited by 2,853
Chapter 9: Analysing Data and Undertaking Meta-Analyses
Deeks, J. J., Higgins, J. P. T., & Altman, D. G. (2008) · Cited by 2,782
Lo, C.-M., Ngan, H., Tso, W.-K., Liu, C.-L., Lam, C.-M., Poon, R. T.-P., Fan, S.-T., & Wong, J. (2002) · Hepatology · doi:10.1053/jhep.2002.33156 · Cited by 2,613
Abraham, J. (2010) · Handbook of Transnational Economic Governance Regimes · doi:10.1163/ej.9789004163300.i-1081.897 · Cited by 2,582
Wood, L., Egger, M., Gluud, L. L., Schulz, K. F., Jüni, P., Altman, D. G., Gluud, C., Martin, R. M., Wood, A. J. G., & Sterne, J. A. C. (2008) · BMJ · doi:10.1136/bmj.39465.451748.ad · Cited by 2,538
Self-citationPrimary liver cancer: Worldwide incidence and trends
Bosch, F. X., Ribes, J., Díaz, M., & Cléries, R. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.011 · Cited by 2,477
Kjaergard, L. L., Villumsen, J., & Gluud, C. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-11-200112040-00010 · Cited by 2,283
Self-citationThe Hazards of Scoring the Quality of Clinical Trials for Meta-analysis
Jüni, P. (1999) · JAMA · doi:10.1001/jama.282.11.1054 · Cited by 1,981
Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis
Wetterslev, J., Thorlund, K., Brok, J., & Gluud, C. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.03.013 · Cited by 1,881
Self-citationUsers' guides to the medical literature : a manual for evidence-based clinical practice
Guyatt, G. H., Rennie, D., Meade, M. O., & Cook, D. J. (2002) · Cited by 1,196
Brok, J., Thorlund, K., Gluud, C., & Wetterslev, J. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.10.007 · Cited by 1,113
Self-citationThe Continuing Increase in the Incidence of Hepatocellular Carcinoma in the United States: An Update
El-Serag, H. B., Davila, J. A., Petersen, N. J., & McGlynn, K. A. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-10-200311180-00009 · Cited by 943
Estimating required information size by quantifying diversity in random-effects model meta-analyses
Wetterslev, J., Thorlund, K., Brok, J., & Gluud, C. (2009) · BMC Medical Research Methodology · doi:10.1186/1471-2288-9-86 · Cited by 938
Self-citationCammà, C., Schepis, F., Orlando, A., Albanese, M., Shahied, L., Trevisani, F., Andreone, P., Craxì, A., & Cottone, M. (2002) · Radiology · doi:10.1148/radiol.2241011262 · Cited by 851
Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?
Thorlund, K., Devereaux, P. J., Wetterslev, J., Guyatt, G., Ioannidis, J. P. A., Thabane, L., Gluud, L.-L., Als-Nielsen, B., & Gluud, C. (2009) · International Journal of Epidemiology · doi:10.1093/ije/dyn179 · Cited by 833
Self-citation(1995) · New England Journal of Medicine · doi:10.1056/nejm199505113321903 · Cited by 809
Royle, P., & Milne, R. (2003) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462303000552 · Cited by 693
Sangiovanni, A., Del Ninno, E., Fasani, P., De Fazio, C., Ronchi, G., Romeo, R., Morabito, A., de Franchis, R., & Colombo, M. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.12.049 · Cited by 600
Section XXIV. Partition Chromatographs
(2009) · Biotechnology · doi:10.1201/9781420084498-31 · Cited by 590
Bruix, J., Llovet, J. M., Castells, A., Montañá, X., Brú, C., Ayuso, M. D. C., Vilana, R., & Rodés, J. (1998) · Hepatology · doi:10.1002/hep.510270617 · Cited by 533
Davila, J. A., Morgan, R. O., Shaib, Y., McGlynn, K. A., & El–Serag, H. B. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.07.020 · Cited by 501
Overcoming the limitations of current meta-analysis of randomised controlled trials
Pogue, J., & Yusuf, S. (1998) · The Lancet · doi:10.1016/s0140-6736(97)08461-4 · Cited by 428
Forner, A., Ayuso, C., Varela, M., Rimola, J., Hessheimer, A. J., de Lope, C. R., Reig, M., Bianchi, L., Llovet, J. M., & Bruix, J. (2009) · Cancer · doi:10.1002/cncr.24050 · Cited by 426
Pelletier, G., Roche, A., Ink, O., Anciaux, M. L., Derhy, S., Rougier, P., Lenoir, C., Attali, P., & Etienne, J.-P. (1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90110-d · Cited by 417
Pelletier, G., Ducreux, M., Gay, F., Luboinski, M., Hagège, H., Thong, D., Van Steenbergen, W., Buffet, C., Rougier, P., Adler, M., et al. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80187-6 · Cited by 396
Multiplicity in randomised trials II: subgroup and interim analyses
Schulz, K. F., & Grimes, D. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66516-6 · Cited by 357
International trends and patterns of primary liver cancer
McGlynn, K. A., Tsao, L., Hsing, A. W., Devesa, S. S., & Fraumeni, J. F. (2001) · International Journal of Cancer · doi:10.1002/ijc.1456 · Cited by 349
Lin, D.-Y., Liaw, Y.-F., Lee, T.-Y., & Lai, C.-M. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90436-2 · Cited by 294
Raoul, J., Guyader, D., Bretagne, J., Heautot, J., Duvauferrier, R., Bourguet, P., Bekhechi, D., Deugnier, Y. M., & Gosselin, M. (1997) · Hepatology · doi:10.1002/hep.510260511 · Cited by 286
Emerson, J. D., Burdick, E., Hoaglin, D. C., Mosteller, F., & Chalmers, T. C. (1990) · Controlled Clinical Trials · doi:10.1016/0197-2456(90)90175-2 · Cited by 241
Wu, C.-C., Ho, Y.-Z., Ho, W. L., Wu, T.-C., Liu, T.-J., & P'Eng, F.-K. (1995) · Journal of British Surgery · doi:10.1002/bjs.1800820141 · Cited by 218
Lu, M., Kuang, M., Liang, L., et al. (2006) · PubMed · Cited by 200
Early stopping of randomized clinical trials for overt efficacy is problematic.
Bassler, D., Montori, V. M., Briel, M., Glasziou, P., & Guyatt, G. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.07.016 · Cited by 130
Doffoël, M., Bonnetain, F., Bouché, O., Vetter, D., Abergel, A., Fratté, S., Grangé, J., Stremsdoerfer, N., Blanchi, A., Bronowicki, J., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.01.004 · Cited by 93
Systematic reviewers neglect bias that results from trials stopped early for benefit
Bassler, D., González, I. F., Briel, M., Cook, D. J., Devereaux, P. J., Heels-Ansdell, D., Kirpalani, H. M., Meade, M. O., Montori, V. M., Rozenberg, A., et al. (2007) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.12.006 · Cited by 63
(2016) · Health at a glance. Asia/Pacific · doi:10.1787/health_glance_ap-2016-graph4-en · Cited by 35
Li, Q., Wang, J., Sun, Y. K., Cui, Y., Juzi, J. T., Qian, B., & Hao, X. (2006) · Digestive Surgery · doi:10.1159/000095396 · Cited by 35
The Impact of Stopping Rules on Heterogeneity of Results in Overviews of Clinical Trials
Hughes, M. D., Freedman, L. S., & Pocock, S. (1992) · Biometrics · doi:10.2307/2532737 · Cited by 35
Randomized Trials Stopped Early for Benefit: A Systematic Review
Montori, V. M., Devereaux, P. J., Adhikari, N. K. J., Burns, K. E. A., Eggert, C. H., Briel, M., Lacchetti, C., Leung, T. W., Darling, E., Bryant, D. M., et al. (2005) · JAMA · doi:10.1001/jama.294.17.2203 · Cited by 26
Hulot, J., Cucherat, M., Charlesworth, A., van Veldhuisen, D. J., Corvol, J., Mallet, A., Boissel, J., Hampton, J., & Lechat, P. P. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01768.x · Cited by 11
Walsh (1995) · doi:10.1002/1097-0142(19951201)76:11
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“[224,225] compared with TACE (22–29”
BackgroundInfluentialAASLD guidelines for the treatment of hepatocellular carcinoma
Heimbach, J. K., Kulik, L. M., Finn, R. S., Sirlin, C. B., Abecassis, M. M., Roberts, L. R., Zhu, A. X., Murad, M. H., & Marrero, J. A. (2018) · Hepatology · doi:10.1002/hep.29086 · Cited by 4,070
Forner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
Metadata
- Authors
- Oliveri, R. S., Wetterslev, J., & Gluud, C.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2011-03-16
- Volume
- 2012
- Issue
- 7
- Pages
- CD004787-CD004787
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1506777089
- Cited by
- 268
- References
- 61
- FWCI
- 16.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.